Abstract: Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease.

Abstract: Disclosed is a method for correlating at least one amino acid sequence from an antibody isolated from human or animal blood with at least one DNA sequence corresponding to the antibody in the immunorepertoire of the human or animal. The method also provides a means for pairing heavy and light chains to produce synthesized monoclonal antibodies.

Abstract: The present disclosure relates to methods for amplifying nucleic acids that avoid problems associated with primer-dimer formation. The present methods are referred to herein as dimer avoided multiplex polymerase chain reaction (dam-PCR). The methods disclosed herein generally comprise the steps of reverse transcribing at least one first strand of DNA, for example cDNA from an RNA sample, wherein each first strand of DNA incorporates a reverse common primer binding site; selecting each first strand of DNA; synthesizing at least one second strand of DNA from each of the at least one first strand of DNA, wherein each second strand of DNA incorporates a forward common primer binding site; selecting each second strand of cDNA; and amplifying the DNA strands using common primers. Alternatively, the method may be performed using a gDNA template.

Abstract: The present disclosure generally pertains to a method for developing diagnostic tests that are based on the immune response and the resulting immune repertoire. The presently disclosed method increases the signal and reduces the background to allow the identification of shared CDR3s that can be used to produce a disease signature. The presently disclosed method may be used to develop a diagnostic test for different diseases including, but not limited to, cancer, autoimmune disease, inflammatory disease and infectious disease.

Abstract: The present disclosure generally pertains to a method for comparing the immunorepertoire diversity of a patient to the shared immunorepertoire of a group of individuals to identify whether the immunorepertoire diversity of the patient is normal or abnormal relative to the shared immunorepertoire of the group of individuals.

Abstract: Disclosed is a method for calculating a Polymerase Preference Index (PPI) for potential primers for DNA sequencing and/or amplification, and thereby increasing the efficiency of DNA sequencing and/or amplification performed using primers selected according to their PPI number.

Abstract: The present disclosure relates to methods for amplifying nucleic acids that avoid problems associated with primer-dimer formation. The present methods are referred to herein as dimer avoided multiplex polymerase chain reaction (dam-PCR). The methods disclosed herein generally comprise the steps of reverse transcribing at least one first strand of DNA, for example cDNA from an RNA sample, wherein each first strand of DNA incorporates a reverse common primer binding site; selecting each first strand of DNA; synthesizing at least one second strand of DNA from each of the at least one first strand of DNA, wherein each second strand of DNA incorporates a forward common primer binding site; selecting each second strand of cDNA; and amplifying the DNA strands using common primers. Alternatively, the method may be performed using a gDNA template.

Abstract: The present invention pertains to methods for determining the change in the immune repertoire of an individual suffering from disease or undergoing therapy for the treatment of a disease. The methods use the difference between the change in the level of immune cell diversity seen in an individual before, during or after a health event to determine the effect of the disease, or the effect of a treatment regime, on the individual. The difference in the level of immune cell diversity is referred to as the Delta Index and is defined as the quantitative and qualitative change (gain or loss of clones) of an individual's most dynamic immune cells over time.

Abstract: The present disclosure generally pertains to a multiplex method for analyzing samples comprising using polynucleotide amplification to produce amplified products wherein one or more target sequences are tagged with a non-interfering, non-canceling target-specific polynucleotide identification tag, pyrosequencing the amplified products through the non-canceling target-specific polynucleotide identification tag sequence to detect the presence of one or more specific polynucleotide identification tags. The presence of a specific polynucleotide identification tag being correlated with the presence of a specific target sequence.

Abstract: The present disclosure generally pertains to a method for comparing the immunorepertoire diversity of a patient to the shared immunorepertoire of a group of individuals to identify whether the immunorepertoire diversity of the patient is normal or abnormal relative to the shared immunorepertoire of the group of individuals.